BIOPHARMA
By
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next Trillion-Dollar Neuroscience Opportunity?
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain barrier (BBB) breakthroughs•…
Is Gilead’s Experimental HIV Treatment Matching the Efficacy of Its Blockbuster Drug in Late-Stage Trials?
Foster City, California — Gilead Sciences has reported that its experimental HIV treatment has met the primary goal…
Is the White House (Trump) Expanding Its Drug Price Reduction Strategy with the Largest Round of Agreements Yet?
Washington, D.C. — The U.S. administration has announced a new set of agreements with nine pharmaceutical companies to…
